INS and type 2 diabetes mellitus: In addition, the supplement caused a significant reduction in the induced hyperglycemia (−120.60 mg/dl, −30.20%, p = .004) compared to insulin (−151.66 mg/dl, −49.80%, p = .001) in type 1 diabetics and it significantly decreased GTT (−159.50 mg/dl, −42.80%, p = .002) respect to glibenclamide (−113.80 mg/dl, −41.10%, p = .001) in T2DM patients, 4 hr later (Taj Eldin et al., 2010).